Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Galai, E. Ozeri
53  Ergebnisse:
Personensuche X
?
1

EPS4.03 ASOs reducing MUC5AC or MUC5B as a therapeutic appr..:

Ozeri Galai, E. ; Oren, Y.S. ; Stampfer, C.D....
Journal of Cystic Fibrosis.  23 (2024)  - p. S44 , 2024
Link: https://doi.org/10.1016/..
 
?
2

WS05.04 SPL84 efficient and durable effect, restoring 3849 ..:

Galai, E. Ozeri ; Oren, Y.S. ; Cheng, Y....
Journal of Cystic Fibrosis.  23 (2024)  - p. S10 , 2024
Link: https://doi.org/10.1016/..
 
?
3

618 SPL84-23-1 antisense oligonucleotide modulating the 384..:

Barchad-Avizur, O. ; Oren, Y. ; Golec, A....
Journal of Cystic Fibrosis.  21 (2022)  - p. S342 , 2022
Link: https://doi.org/10.1016/..
 
?
4

P028 Antisense oligonucleotide splicing modulation as a nov..:

Barchad, O. Avizur ; Oren, Y.S. ; Galai, E. Ozeri...
Journal of Cystic Fibrosis.  21 (2022)  - p. S68 , 2022
Link: https://doi.org/10.1016/..
 
?
5

P029 Antisense oligonucleotide-based drug development for c..:

Oren, Y.S. ; Barchad, O. Avizur ; Galai, E. Ozeri...
Journal of Cystic Fibrosis.  21 (2022)  - p. S68 , 2022
Link: https://doi.org/10.1016/..
 
?
6

604 SpliSense's antisense oligonucleotide SPL84-23-1 proper..:

Ozeri Galai, E. ; Friedman, L. ; Tilley, S....
Journal of Cystic Fibrosis.  21 (2022)  - p. S335 , 2022
Link: https://doi.org/10.1016/..
 
?
7

ePS6.07 SpliSense's ASO SPL84-23-1 properly distributes and..:

Hart, G. ; Galai, E. Ozeri ; Friedman, L....
Journal of Cystic Fibrosis.  21 (2022)  - p. S59-S60 , 2022
Link: https://doi.org/10.1016/..
 
?
8

615 Antisense oligonucleotide-based drug development for pe..:

Oren, Y. ; Barchad, O. Avizur ; Galai, E. Ozeri...
Journal of Cystic Fibrosis.  21 (2022)  - p. S340-S341 , 2022
Link: https://doi.org/10.1016/..
 
?
9

619 Antisense oligonucleotide splicing modulation as a nove..:

Avizur Barchad, O. ; Oren, Y. ; Ozeri Galai, E....
Journal of Cystic Fibrosis.  21 (2022)  - p. S342 , 2022
Link: https://doi.org/10.1016/..
 
?
10

620 Antisense oligonucleotide splicing modulation as a nove..:

Oren, Y. ; Barchad-Avizur, O. ; Galai, E. Ozeri...
Journal of Cystic Fibrosis.  21 (2022)  - p. S342-S343 , 2022
Link: https://doi.org/10.1016/..
 
?
11

P014 Safety and toxicity profile of SPL84, an inhaled antis..:

Hart, G. ; Barchad-Avitzur, O. ; Friedman, L....
Journal of Cystic Fibrosis.  22 (2023)  - p. S67-S68 , 2023
Link: https://doi.org/10.1016/..
 
?
12

231 Safety and toxicity profile of SPL84, an inhaled antise..:

Friedman, L. ; Barchad-Avitzur, O. ; Dahan, S....
Journal of Cystic Fibrosis.  22 (2023)  - p. S118 , 2023
Link: https://doi.org/10.1016/..
 
?
13

WS09.03 Delivery characterisation of SPL84 Inhaled Antisens..:

Ozeri-Galai, E. ; Friedman, L. ; Markovetz, M....
Journal of Cystic Fibrosis.  22 (2023)  - p. S18-S19 , 2023
Link: https://doi.org/10.1016/..
 
?
14

235 Reducing MUC5AC or MUC5B expression using antisense oli..:

Oren, Y. ; Stampfer, C. ; Elgrabli, R....
Journal of Cystic Fibrosis.  22 (2023)  - p. S120-S121 , 2023
Link: https://doi.org/10.1016/..
 
?
15

236 SPL84, an antisense oligonucleotide modulating the 3849..:

Barchad-Avitzur, O. ; Oren, Y. ; Stampfer, C....
Journal of Cystic Fibrosis.  22 (2023)  - p. S121 , 2023
Link: https://doi.org/10.1016/..
 
1-15